Thursday, May 19, 2016 - 12:00

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’) the global pharmaceutical and services company, officially opened its new US headquarters last night at a reception attended by members of local government, leading pharmaceutical and biotech companies and the US Director of the British Government’s international commercial arm, UK Trade & Investment (“UKTI”).

The office in Yardley, PA combines the Group’s existing operations in Philadelphia, PA and Princeton, NJ following Clinigen’s acquisition of Idis in April 2015, providing a dedicated base for the Group’s 30-strong integrated and expanding US team of patient access experts.

The office will accommodate employees from Clinigen’s Clinical Trial Services (CTS) division, the global market leader in the management and supply of medicines for clinical trials, and Idis Managed Access (MA), the leading provider of early access programs for innovative new medicines. These teams have relocated from the Philadelphia and Princeton sites respectively.

The move to Yardley is part of Clinigen’s ongoing strategy to strengthen its US presence and enables further expansion as the business continues to grow. It also follows Clinigen’s strategic alliance, agreed last year, with Nashville-based Cumberland Pharmaceuticals to provide complementary support in the development, marketing, promotion and distribution of the Group’s products in the US.

Clinigen marked the opening of the office with a reception on Wednesday 18 May 2016 attended by leading pharmaceutical companies, patient organizations and government officials, with special guests from the UK Trade & Investment.

Martin Cook, Deputy Consul General New York and Director of UKTI USA

“It has been fantastic to work alongside the Clinigen team to help facilitate the consolidation of the Group’s operations in the US as they complete the integration of their business. We are very pleased to see such an innovative, rapidly growing and unique UK company expanding and attracting the industry’s best talent in what is such an important market. We wish Clinigen every success.”

John B. Lewis, Vice Chair, Board of Supervisors, Lower Makefield Township, PA

“Pennsylvania has become a hub for cutting edge pharmaceutical and biotechnology companies and I would like to personally welcome Clinigen to the area. We are encouraged to see international market-leading life science organisations like Clinigen opting to locate its facilities in Yardley; especially a company so focused on providing patients with access to the often life-saving, medicines they need.”

Steve Glass, Group Managing Director, Clinigen Group said:

“Yardley’s close proximity to both New York and Philadelphia and its location in an area of specialist pharmaceutical expertise made it an ideal location for our fully integrated US services team. One year on from our acquisition of Idis we now have a better, stronger, market leading business ideally positioned to provide the right medicine to the right patient at the right time in the important US market and across the world.”

- Ends -

 

Contact Details

Please contact Instinctif Partners for photos of the official opening reception if required.

Clinigen Group plc
Tel: +44 (0) 1283 495 010
Peter George, Group Chief Executive Officer    
Shaun Chilton, Group Deputy Chief Executive Officer    
Martin Abell, Chief Financial Officer 

Instinctif Partners (media relations)    
Tel: +44 (0) 20 7457 2020
Melanie Toyne-Sewell / Jen Lewis / Emma Barlow    
Email: clinigen@instinctif.com

 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time.

The Group consists of five synergistic businesses focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.

The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions: Idis Managed Access runs early access programs for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).

Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital commercial products.
For more information, please visit www.clinigengroup.com

About UKTI

UK Trade & Investment USA helps UK-based companies expand business globally to the United States and helps American companies bring their high-quality investment to the UK’s dynamic economy. UKTI offers expertise and contacts through its extensive network of specialists in the UK, and in British embassies and other diplomatic offices around the world. They provide companies with the tools they require to be competitive on the world stage.

The team in the United States works to promote UK-US trade and investment through our offices at the British Embassy in Washington as well as the British Consulates General in Atlanta, Boston, Chicago, Houston, Los Angeles, Miami, New York and San Francisco.

 

 

Back to News